ijms-logo

Journal Browser

Journal Browser

Vaccine Research and Adjuvant Discovery

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: 20 June 2025 | Viewed by 2985

Special Issue Editor


E-Mail Website
Guest Editor
Department of Chemistry, University of Montana, 32 Campus Drive, Missoula, MT 59812, USA
Interests: cancer therapy

Special Issue Information

Dear Colleagues,

The insidious threat posed by emerging infectious diseases requires the development of novel and highly effective vaccine strategies that provide both immediate short-term and durable long-term antigen-specific immunity. Especially vulnerable to these threats are high-risk populations, such as the elderly, newborns, and immune-compromised individuals. Many new vaccines include the use of synthetic and recombinant subunit antigens to improve manufacturability and safety but unfortunately often result in decreased vaccine potency and long-term efficacy. In addition, conventional vaccines need to be administered multiple times, can take a long time to build up protective antibodies, and often provide weak and/or waning protection in infants and the elderly. One way to circumvent these issues is the use of next-generation adjuvants. However, despite many decades of development, only a few adjuvants are currently licensed for use in vaccines. Moreover, the majority of existing vaccines contain a single adjuvant, and recent evidence suggests that this is unlikely to be sufficient for the induction of a protective immune response against many emerging infectious diseases. The future of vaccines, as arguably the most impactful medical achievement of our time, potentially rests on the discovery and development of new technologies. This is particularly critical for new pathogens and those maladies that are the most difficult to treat using conventional vaccine strategies. The success of RNA vaccines for COVID-19 and adjuvanted vaccines for shingles highlight the future and the breadth of work still to be carried out. This Special Issue will attempt to highlight efforts toward new vaccine and adjuvant technologies.

Dr. Kendal Ryter
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • C-type lectin receptor
  • mincle
  • toll-like receptor

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 2948 KiB  
Article
High-Throughput Luminescence-Based Serum Bactericidal Assay Optimization and Characterization to Assess Human Sera Functionality Against Multiple Shigella flexneri Serotypes
by Valentina Caradonna, Marika Pinto, Renzo Alfini, Carlo Giannelli, Miren Iturriza, Francesca Micoli, Omar Rossi and Francesca Mancini
Int. J. Mol. Sci. 2024, 25(20), 11123; https://doi.org/10.3390/ijms252011123 - 16 Oct 2024
Viewed by 1037
Abstract
Shigellosis represents a significant global health concern particularly affecting children under 5 years in low- and middle-income countries (LMICs) and is associated with stunting and antimicrobial resistance. There is a critical need for an effective vaccine offering broad protection against the different Shigella [...] Read more.
Shigellosis represents a significant global health concern particularly affecting children under 5 years in low- and middle-income countries (LMICs) and is associated with stunting and antimicrobial resistance. There is a critical need for an effective vaccine offering broad protection against the different Shigella serotypes. A correlate of protection has not yet been established but there is a general consensus about the relevant role of anti-O-Antigen-specific IgG and its functionality evaluated by the Serum Bactericidal Assay (SBA). This study aims to characterize a high-throughput luminescence-based SBA (L-SBA) against seven widespread Shigella serotypes. The assay was previously developed and characterized for S. sonnei and S. flexneri 1b, 2a, and 3a and has now been refined and extended to an additional five serotypes (S. flexneri 4a, 5b, 6, X, and Y). The characterization of the assay with human sera confirmed the repeatability, intermediate precision, and linearity of the assays; both homologous and heterologous specificity were verified as well; finally, limit of detection and quantification were established for all assays. Moreover, different sources of baby rabbit complement showed to have no impact on L-SBA output. The results obtained confirm the possibility of extending the L-SBA to multiple Shigella serotypes, thus enabling analysis of the functional response induced by natural exposure to Shigella in epidemiological studies and the ability of candidate vaccines to elicit cross-functional antibodies able to kill a broad panel of prevalent Shigella serotypes in a complement-mediated fashion. Full article
(This article belongs to the Special Issue Vaccine Research and Adjuvant Discovery)
Show Figures

Figure 1

19 pages, 3222 KiB  
Article
Systematic Evaluation of Regiochemistry and Lipidation of Aryl Trehalose Mincle Agonists
by Asia Marie S. Riel, Viktoria Rungelrath, Tamer A. Elwaie, Omer K. Rasheed, Linda Hicks, George Ettenger, Dai-Chi You, Mira Smith, Cassandra Buhl, Walid Abdelwahab, Shannon M. Miller, Alyson J. Smith, David Burkhart, Jay T. Evans and Kendal T. Ryter
Int. J. Mol. Sci. 2024, 25(18), 10031; https://doi.org/10.3390/ijms251810031 - 18 Sep 2024
Cited by 1 | Viewed by 1359
Abstract
The Macrophage-Inducible C-type Lectin receptor (Mincle) plays a critical role in innate immune recognition and pathology, and therefore represents a promising target for vaccine adjuvants. Innovative trehalose-based Mincle agonists with improved pharmacology and potency may prove useful in the development of Th17-mediated adaptive [...] Read more.
The Macrophage-Inducible C-type Lectin receptor (Mincle) plays a critical role in innate immune recognition and pathology, and therefore represents a promising target for vaccine adjuvants. Innovative trehalose-based Mincle agonists with improved pharmacology and potency may prove useful in the development of Th17-mediated adaptive immune responses. Herein, we report on in vitro and in silico investigations of specific Mincle ligand–receptor interactions required for the effective receptor engagement and activation of Th17-polarizing cytokines. Specifically, we employed a library of trehalose benzoate scaffolds, varying the degree of aryl lipidation and regiochemistry that produce inflammatory cytokines in a Mincle-dependent fashion. In vitro interleukin-6 (IL-6) cytokine production by human peripheral blood mononuclear cells (hPBMCs) indicated that the lipid regiochemistry is key to potency and maximum cytokine output, with the tri-substituted compounds inducing higher levels of IL-6 in hPBMCs than the di-substituted derivatives. Additionally, IL-6 production trended higher after stimulation with compounds that contained lipids ranging from five to eight carbons long, compared to shorter (below five) or longer (above eight) carbon chains, across all the substitution patterns. An analysis of the additional cytokines produced by hPBMCs revealed that compound 4d, tri-substituted and five carbons long, induced significantly greater levels of interleukin-1β (IL-1β), tumor necrosis factor- α (TNF-α), interleukin-23 (IL-23), and interferon- γ (IFN-γ) than the other compounds tested in this study. An in silico assessment of 4d highlighted the capability of this analogue to bind to the human Mincle carbohydrate recognition domain (CRD) efficiently. Together, these data highlight important structure–activity findings regarding Mincle-specific cytokine induction, generating a lead adjuvant candidate for future formulations and immunological evaluations. Full article
(This article belongs to the Special Issue Vaccine Research and Adjuvant Discovery)
Show Figures

Graphical abstract

Back to TopTop